Olutasidenib
3 abstracts
Abstract
Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.Org: Rigel Pharmaceuticals, Inc.,
Abstract
Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.Org: Georgia Cancer Center, Augusta University, Augusta University/University of Georgia Medical Partnership, School of Medicine, Zhejiang University, Hangzhou, China, University of California, Davis Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL,
Abstract
Olutasidenib in post-venetoclax patients with mIDH1 AML.Org: Georgia Cancer Center, Augusta University, Medical College of Georgia at Augusta University, Augusta, GA, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA,